VivoSim Labs (VIVS) Competitors $4.78 +0.59 (+14.08%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsSEC FilingsShort InterestTrendsBuy This Stock VIVS vs. ITRM, KLTO, SNTI, OKUR, PYRGF, RVPH, RNTX, KZR, MAAQ, and CASIShould you be buying VivoSim Labs stock or one of its competitors? The main competitors of VivoSim Labs include Iterum Therapeutics (ITRM), Klotho Neurosciences (KLTO), Senti Biosciences (SNTI), OnKure Therapeutics (OKUR), PyroGenesis Canada (PYRGF), Reviva Pharmaceuticals (RVPH), Rein Therapeutics (RNTX), Kezar Life Sciences (KZR), Mana Capital Acquisition (MAAQ), and CASI Pharmaceuticals (CASI). These companies are all part of the "pharmaceutical products" industry. VivoSim Labs vs. Its Competitors Iterum Therapeutics Klotho Neurosciences Senti Biosciences OnKure Therapeutics PyroGenesis Canada Reviva Pharmaceuticals Rein Therapeutics Kezar Life Sciences Mana Capital Acquisition CASI Pharmaceuticals Iterum Therapeutics (NASDAQ:ITRM) and VivoSim Labs (NASDAQ:VIVS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, earnings, media sentiment, profitability, institutional ownership and dividends. Is ITRM or VIVS more profitable? Iterum Therapeutics has a net margin of 0.00% compared to VivoSim Labs' net margin of -1,396.48%. Iterum Therapeutics' return on equity of 0.00% beat VivoSim Labs' return on equity.Company Net Margins Return on Equity Return on Assets Iterum TherapeuticsN/A N/A -65.01% VivoSim Labs -1,396.48%-32.95%-21.31% Does the media refer more to ITRM or VIVS? In the previous week, Iterum Therapeutics and Iterum Therapeutics both had 2 articles in the media. Iterum Therapeutics' average media sentiment score of 1.45 beat VivoSim Labs' score of 0.95 indicating that Iterum Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Iterum Therapeutics Positive VivoSim Labs Positive Do insiders and institutionals have more ownership in ITRM or VIVS? 9.2% of Iterum Therapeutics shares are held by institutional investors. Comparatively, 8.2% of VivoSim Labs shares are held by institutional investors. 2.4% of Iterum Therapeutics shares are held by company insiders. Comparatively, 3.7% of VivoSim Labs shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has preferable earnings and valuation, ITRM or VIVS? VivoSim Labs has higher revenue and earnings than Iterum Therapeutics. Iterum Therapeutics is trading at a lower price-to-earnings ratio than VivoSim Labs, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIterum TherapeuticsN/AN/A-$24.77M-$0.85-0.80VivoSim Labs$142K87.52-$2.48M-$10.20-0.47 Which has more risk and volatility, ITRM or VIVS? Iterum Therapeutics has a beta of 3.04, indicating that its stock price is 204% more volatile than the S&P 500. Comparatively, VivoSim Labs has a beta of 1.11, indicating that its stock price is 11% more volatile than the S&P 500. Do analysts prefer ITRM or VIVS? Iterum Therapeutics currently has a consensus price target of $9.00, indicating a potential upside of 1,215.79%. Given Iterum Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Iterum Therapeutics is more favorable than VivoSim Labs.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Iterum Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00VivoSim Labs 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryIterum Therapeutics beats VivoSim Labs on 9 of the 14 factors compared between the two stocks. Get VivoSim Labs News Delivered to You Automatically Sign up to receive the latest news and ratings for VIVS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VIVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VIVS vs. The Competition Export to ExcelMetricVivoSim LabsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$12.43M$3.10B$5.75B$10.27BDividend YieldN/A2.32%5.72%4.60%P/E Ratio-0.4721.3874.9226.41Price / Sales87.52243.79457.0188.61Price / CashN/A44.4425.8129.91Price / Book0.869.6413.256.28Net Income-$2.48M-$53.20M$3.29B$270.38M7 Day Performance91.97%0.44%0.47%2.70%1 Month Performance170.06%4.26%4.59%5.99%1 Year PerformanceN/A9.43%73.41%25.94% VivoSim Labs Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VIVSVivoSim Labs0.4298 of 5 stars$4.78+14.1%N/AN/A$12.43M$142K-0.4720News CoverageITRMIterum Therapeutics3.0135 of 5 stars$0.73+3.4%$9.00+1,141.4%-37.4%$34.10MN/A-0.8510Positive NewsShort Interest ↓Gap UpKLTOKlotho Neurosciences0.4243 of 5 stars$0.55+3.1%N/AN/A$34.04MN/A-1.23N/ASNTISenti Biosciences3.3708 of 5 stars$1.29-0.8%$8.50+558.9%-56.0%$33.75M$2.56M-0.144Positive NewsShort Interest ↓OKUROnKure Therapeutics3.7456 of 5 stars$2.49-3.3%$32.33+1,201.1%N/A$33.62MN/A-0.52N/APYRGFPyroGenesis CanadaN/A$0.18-0.5%N/A-67.9%$32.84M$9.14M-2.9290RVPHReviva Pharmaceuticals3.1408 of 5 stars$0.45-0.2%$5.20+1,065.9%-63.1%$30.26MN/A-0.685News CoverageAnalyst ForecastRNTXRein Therapeutics0.9859 of 5 stars$1.28-2.3%N/AN/A$29.83MN/A-0.489Gap DownKZRKezar Life Sciences3.6174 of 5 stars$4.06+0.9%$9.00+121.9%-30.7%$29.70MN/A-0.4260News CoverageAnalyst UpgradeGap DownMAAQMana Capital AcquisitionN/A$3.63-2.2%N/A+1,169.3%$29.49MN/A0.001CASICASI Pharmaceuticals3.7602 of 5 stars$2.38+1.5%$4.00+68.4%-68.2%$29.21M$28.54M-0.82180 Related Companies and Tools Related Companies Iterum Therapeutics Alternatives Klotho Neurosciences Alternatives Senti Biosciences Alternatives OnKure Therapeutics Alternatives PyroGenesis Canada Alternatives Reviva Pharmaceuticals Alternatives Rein Therapeutics Alternatives Kezar Life Sciences Alternatives Mana Capital Acquisition Alternatives CASI Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VIVS) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VivoSim Labs, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share VivoSim Labs With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
